{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:45:34Z","timestamp":1770486334789,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009993","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000}}],"reference-count":42,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009993.pub2","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T13:10:18Z","timestamp":1409577018000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Interleukin-1 inhibitors for acute gout"],"prefix":"10.1002","volume":"2014","author":[{"given":"Francisca","family":"Sivera","sequence":"first","affiliation":[{"name":"Hospital de Elda; Servicio de Reumatologia; Ctra. Elda-Sax, PTDA. La Torreta, S\/N Elda (Alicante) Spain 03600"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihir D","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"Repatriation General Hospital; Rheumatology Unit; Daws Road Daw Park South Australia Australia 5041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Alicante; Secci\u00f3n de Reumatolog\u00eda; C\/ Pintor Baeza, 12 Alicante Spain 03010"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash Department of Clinical Epidemiology, Cabrini Hospital; Suite 41, Cabrini Medical Centre 183 Wattletree Road Malvern Victoria Australia 3144"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[{"name":"Instituto de Salud Musculoesquel\u00e9tica; Calle Ofelia Nieto, 10 Madrid Spain 28039"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,1]]},"reference":[{"key":"10.1002\/14651858.CD009993.pub2-BIB0001|cit1","unstructured":"NCT01029652 Canakinumab in the treatment of acute gout flares and prevention of new flares in patients unable to use non-steroidal anti-inflammatory drugs (NSAIDs) and\/or colchicine including a 12 weeks extension and an open-label 48 weeks extension study (\u03b2-RELIEVED) clinicaltrials.gov\/show\/NCT01029652"},{"issue":"11","key":"10.1002\/14651858.CD009993.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0003|cit3","unstructured":"NCT01080131 Canakinumab in the treatment of acute gout flares and prevention of new flares in patients unable to use non-steroidal anti-inflammatory drugs (NSAIDs) and\/or colchicines including a 12 week extension and a 1 year open-label extension study (\u03b2-RELIEVED-II) clinicaltrials.gov\/show\/NCT01080131"},{"issue":"11","key":"10.1002\/14651858.CD009993.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0005|cit5","unstructured":"NCT00798369 Targeted dose finding of canakinumab (ACZ885) for management of acute flare in refractory or contraindicated gout patients clinicaltrials.gov\/show\/NCT00798369"},{"issue":"2","key":"10.1002\/14651858.CD009993.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult to treat gout arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Research & Therapy"},{"issue":"10","key":"10.1002\/14651858.CD009993.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar4159","article-title":"Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator","volume":"15","author":"Terkeltaub","year":"2013","journal-title":"Arthritis Research & Therapy"},{"issue":"2","key":"10.1002\/14651858.CD009993.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.reuma.2010.02.001","article-title":"Systematic review: safety and efficacy of anti-TNF in elderly patients","volume":"7","author":"Busquets","year":"2011","journal-title":"Reumatologia Clinica"},{"issue":"3","key":"10.1002\/14651858.CD009993.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study","volume":"82","author":"Campion","year":"1987","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0011|cit11","unstructured":"Cates C Dr Chris Cates' EBM web site. Visual Rx version 3 www.nntonline.net\/visualrx"},{"issue":"8","key":"10.1002\/14651858.CD009993.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0013|cit13","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"8","key":"10.1002\/14651858.CD009993.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/ard.2008.094201","article-title":"Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography","volume":"68","author":"Dalbeth","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0015|cit15","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD009993.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0017|cit17","unstructured":"Food Drug Administration Center for Drug Evaluation and Research Summary minutes of the Arthritis Advisory Committee meeting June 21, 2011 www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM267388.pdf"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3899\/jrheum.090371","article-title":"Progress in measurement instruments for acute and chronic gout studies","volume":"36","author":"Grainger","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.1780160402","article-title":"The past four decades of progress in the knowledge of gout with and assessment of present status","volume":"16","author":"Gutman","year":"1973","journal-title":"Arthritis & Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD009993.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/ard.2006.051649","article-title":"Sex differences in gout epidemiology: evaluation and treatment","volume":"65","author":"Harrold","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0021|cit21","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0022|cit22","unstructured":"Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0023|cit23","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"10","key":"10.1002\/14651858.CD009993.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis in acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care and Research"},{"issue":"12","key":"10.1002\/14651858.CD009993.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub2","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1002\/14651858.CD009993.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pain.2010.05.011","article-title":"\"Evidence\" in chronic pain - establishing best practice in the reporting of systematic reviews","volume":"150","author":"Moore","year":"2010","journal-title":"Pain"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Gout","volume":"364","author":"Neogi","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0029|cit29","unstructured":"National Institute for Health and Care Excellence Gouty arthritis: canakinumab www.nice.org.uk\/Advice\/ESNM23"},{"issue":"8","key":"10.1002\/14651858.CD009993.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/RHU.0b013e3182314d40","article-title":"An audit of the variability of diagnosis and management of gout in the rheumatology setting: the Gout Evaluation and Management Study","volume":"17","author":"Perez-Ruiz","year":"2011","journal-title":"Journal of Clinical Rheumatology"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0032|cit32","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"17","key":"10.1002\/14651858.CD009993.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1517\/14656566.2010.529432","article-title":"Colchicine for the treatment of gout","volume":"11","author":"Richette","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD009993.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult to treat gout arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Research and Therapy"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0035|cit35","first-page":"2452","article-title":"Outcome measures for acute and chronic gout","volume":"32","author":"Schumacher","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD009993.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0037|cit37","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0038|cit38","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD009993.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.berh.2010.10.004","article-title":"Epidemiology of gout: an update","volume":"24","author":"Smith","year":"2010","journal-title":"Best Practice & Research Clinical Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD009993.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0041|cit41","unstructured":"Sterne JAC Egger M Moher D Cochrane Bias Methods Group Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009993.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis & Rheumatism"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009993.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T06:32:01Z","timestamp":1708756321000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009993.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009993.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,1]]}}}